<DOC>
	<DOCNO>NCT02119390</DOCNO>
	<brief_summary>Although effective treatment currently available treat human immunodeficiency virus ( HIV ) , retrovirus lead acquire immune deficiency syndrome ( AIDS ) , strict adherence treatment regimen require . Nonadherence highly active antiretroviral therapy ( HAART ) regimens well documented individual HIV . This especially true adolescent young adult ( AYA ) , rate adherence range 20 100 % . Nonadherence significant implication subsequent treatment response health outcome , include poor virologic response , development drug resistance , mortality . Of note , previous research suggest every 1 % increase nonadherence relate 2 % increase likelihood detectable viral load ( VL ) youth behaviorally acquire HIV . Furthermore , high VL salient variable relate increased risk virus transmission . Thus , nonadherence HAART significant public health issue . The objective propose research plan systematically examine individualize , behavioral intervention target HAART nonadherence AYAs initiate HAART . The current intervention support AYA participation brief , staff-delivered instruction adherence-promotion skill . Individualized behavioral analysis motivational interviewing apply provide effective solution current barrier HAART adherence HAART initiation , recommend Panel Antiretroviral Guidelines Adults Adolescents .</brief_summary>
	<brief_title>Medication Adherence Human Immunodeficiency Virus ( HIV )</brief_title>
	<detailed_description>The propose pilot study utilize randomize controlled trial estimate feasibility , acceptability , preliminary efficacy novel intervention AYAs diagnose behaviorally-acquired HIV initiate HAART . Standard care HIV St. Jude Children 's Research Hospital ( SJCRH ) include placebo pill trial ass patient readiness therapy prior start HAART . Participants study randomize either : control arm standard therapy , standard therapy plus individualized behavioral , staff-delivered intervention ( Pill Trial+ ) . Participants control arm receive standard clinical care . Participants Pill Trial+ arm receive standard therapy plus three 25-minute individualize , behavioral , staff-delivered intervention session HAART initiation , 1- , 3-month follow-up visit . Two brief booster session also provide Pill Trial+ arm follow session 1 ( clinic ) 2 ( phone ) . In-person intervention session questionnaire complete conjunction schedule clinical care visit . Sessions measure complete phone designate time point participant becomes unavailable return clinic due extenuate circumstance . As recommended Panel guideline , discussion placebo pill trial adherence first 25-minute session provide novel mechanism discus barrier adherence provide intervention prior HAART initiation . Remaining session promote adherence follow HAART initiation use behavioral problem-solving motivational interviewing strategy . Primary Objective : - To estimate ) rate consent randomize trial b ) differences intervention control condition respect HAART adherence , measure pill count . Secondary Objectives : - To estimate difference intervention control condition respect measure adherence , include HAART self-reported adherence , HAART pharmacy refill , clinic attendance . - To examine disease patient-reported outcome first 6 month follow HAART initiation relationship participation Pill Trial+ intervention .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Behaviorally acquire HIV diagnosis , confirm via medical chart review . Currently follow St. Jude Children 's Research Hospital ( SJCRH ) HIV clinic . Initiating HAART . Recommended placebo trial . 1324 year age time study entry . If 15 year age , willing give inform consent . If age 15 , willing give assent accompany legal guardian/representative give inform consent . Fluent English Previous HAART exposure . Unable understand English and/or cognitively intact ( know IQ &lt; 70 ) study questionnaire understood complete . Pregnant female . Enrolled another protocol exclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adolescent</keyword>
	<keyword>young adult</keyword>
	<keyword>medication adherence</keyword>
</DOC>